----------------------------
OMB APPROVAL
----------------------------
OMB Number: 3235-0145
----------------------------
Expires: December 31, 2005
----------------------------
Estimated average burden
hours per response. . . 11
----------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(AMENDMENT NO. 1)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Bentley Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.02 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
082657 10 7
--------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2003
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 082657 10 7 13G/A Page 2 of 5 Pages
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. Identification Nos. of above person
James R. Murphy
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 1,031,963
SHARES -------------------------------------------------------------
BENEFICIALLY
OWNED BY 6 SHARED VOTING POWER
EACH 0
REPORTING -------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH
1,031,963
-------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,031,963
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.8%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 082657 10 7 13G/A Page 3 of 5 Pages
--------------------------------------------------------------------------------
Item 1(a) NAME OF ISSUER:
Bentley Pharmaceuticals, Inc.
Item 1(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
Bentley Park
2 Holland Way
Exeter, NH 03833
Item 2(a) NAME OF PERSON FILING:
James R. Murphy
Item 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Bentley Park
2 Holland Way
Exeter, NH 03833
Item 2(c) CITIZENSHIP:
United States
Item 2(d) TITLE OF CLASS OF SECURITIES:
Common Stock, par value $.02
Item 2(e) CUSIP NUMBER:
082657 10 7
Item 3 IF THIS STATEMENT IS FILED PURSUANT TO 240.13d-1(b) or
240.13d-2(b) or (c):
Not applicable.
Item 4 OWNERSHIP:
(a) Amount Beneficially Owned: 1,031,963 shares*
(b) Percent of Class: 4.8%
(c) Number of shares as to which the person has:
i. sole power to vote or to direct the vote:
1,031,963 shares*
CUSIP No. 082657 10 7 13G/A Page 4 of 5 Pages
--------------------------------------------------------------------------------
ii. shared power to vote or direct the vote: 0
iii. sole power to dispose or to direct the
disposition of: 1,031,963 shares*
iv. shared power to dispose or to direct the
disposition of: 0
* includes 700 shares owned by Reporting
Person's sons, as to which Reporting Person
disclaims beneficial ownership; also
includes 902,000 shares issuable upon the
exercise of options which are exercisable
within 60 days but are not currently
outstanding
Item 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
Not applicable.
Item 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON:
Not applicable.
Item 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY:
Not applicable.
Item 8 IDENTIFICATION AND CLASSIFICATION OF MEMBER OF THE GROUP:
Not applicable.
Item 9 NOTICE OF DISSOLUTION OF GROUP:
Not applicable.
Item 10 CERTIFICATION:
Not applicable.
CUSIP No. 082657 10 7 13G/A Page 5 of 5 Pages
--------------------------------------------------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
February 12, 2004
------------------------------------------
Date
/S/ JAMES R. MURPHY
------------------------------------------
Signature
James R. Murphy
------------------------------------------
Name/Title